
The Stem Cell Podcast Ep. 51: Stem Cell Theranostics Featuring Dr. Chris Armstrong
Aug 18, 2015
Dr. Chris Armstrong, CEO of Stem Cell Theranostics and expert in molecular biology, discusses innovative uses of iPSCs to model cardiovascular diseases. He explains how his company combines diagnostics with therapeutics to advance drug discovery. The conversation dives into techniques for screening therapies and assessing drug-induced cardiotoxicity. They also touch on the regulatory landscape around iPSC models, emphasizing their potential role in personalized medicine. Chris's journey from academia to biotech leadership adds a personal touch to the scientific insights.
AI Snips
Chapters
Transcript
Episode notes
iPSC-Based Heart Disease Modeling
- Stem Cell Theranostics uses iPSC technology to model inherited heart diseases and screen for drugs.
- The company pairs patient-derived cardiomyocytes with assays to find therapies and detect cardiotoxicity.
Theranostics: Diagnostics Plus Therapeutics
- Theranostics combines therapeutics and diagnostics using stem cell platforms to leave company direction open.
- The name reflects a strategy to pursue both therapies and diagnostic tools with iPSC tech.
Disease Phenotypes Visible In Dish
- Patient-derived cardiomyocytes show disease-specific phenotypes like hypertrophy or weak contraction in vitro.
- Those phenotypes let researchers screen compounds that correct electrical or contractile dysfunction.
